[ Inside the business ]
ACXP stock analysis
ACXP · Acurx Pharmaceuticals, Inc.
Pharmaceutical preparations.
Watch: a leadership change.
The future, in 7 questions
Needs today's sales, share count and price.
- Going-concern warning
- Heavy dilution
From SEC filings, price and Radar. Not advice.
The record
Early signals
Quiet.
A leadership change was filed on Nov 13.
Early signals
Quiet.
What just happened
Signals in the filings
Early signals· full write-up
Quiet.
Early signals Quiet
What's changing in the filings before it shows up in yearly results. Signals, not predictions.
New since last 10-Q (Nov 12, 2026)
Nov 20, 2026 · Other event. Acurx Pharmaceuticals, Inc. (the "Company") deeply regrets to announce that Thomas Harrison, a member of the Board of Directors of the Company since 2021, unexpectedly passed away November 18, 2026. From 8-KNov 13, 2026 · Executive or director change. Joseph C. From 8-KSignals in the filings
What could go wrong
Steadier than most.
It has moved -2.0× the market. In the 2022 rate shock it fell 31% while the market fell 24%. Debt is covered by cash.
What could go wrong
Steadier than most.
Red-flag scan, last 3 years
Past shocks replayed stock S&P 500
Cash vs. debt
What could go wrong· full write-up
Steadier than most.
8 · What could go wrong
Warning signs in the filings, debt, how it reacts to the economy, and the risks it names
Red-flag scan, last 3 years
Modeled on the SEC's published Accounting Quality Model description, not SEC scores
Debt and leverage as of Sep 30, 2026
Macro risk 63 months to Oct 2026 Calculated
Stress test: past shocks replayed stock vs. S&P 500, month-end prices
Right now: last 3 months Reported
What if the market falls?
Historically, about 40% for this stock
Based on its -1.98× pattern. Real moves vary a lot, as the stress test shows.
Speculative check
Speculative.
Speculative: going-concern warning; operating loss, cash flowing out of operations, under $1B in sales; penny stock: under $5 a share with under $6M revenue. Cash runway: 1.4 years.
Speculative check
Speculative.
Why: going-concern warning, operating loss, cash flowing out of operations, under $1B in sales, penny stock: under $5 a share with under $6M revenue.
Speculative check· full write-up
Speculative.
Speculative check: does the business pay for itself?
Self-funding: every condition true, across all three statements. Income statement: revenue of $100M or more, a gross profit, an operating profit, a net profit (last 12 months) and a profit in the latest quarter. Balance sheet: current ratio of 1 or more, positive equity, debt manageable (cash at least the debt, or debt no more than 4 years of operating profit before depreciation). Cash flow: positive cash from operations and positive free cash flow. Plus: new shares under 5% a year, no going-concern warning, Altman Z-score out of the distress zone and a Piotroski F-score of 4 or more. Companies with both profits and positive operating cash are excused negative equity and a low Altman score (buybacks), a current ratio under 1 and negative free cash flow (heavy investment). Speculative: an operating loss, cash flowing out of operations and under $1B in sales (however much cash it has raised, even if one-off gains made a net profit); or a going-concern warning; or a penny stock (under $5 a share with under $6M revenue). Not classified: everything else, with the reasons listed. Tests that don't apply (like gross margin for banks) are left out. Calculated
Why Speculative: going-concern warning; operating loss, cash flowing out of operations, under $1B in sales; penny stock: under $5 a share with under $6M revenue.
Verdict: Speculative, 7 of 11 tests red. Numbers to Dec 31, 2025. Calculated
Net profit: −$8M (last 12 months). Is it making money after all costs? Losses aren't bad by themselves, but they mean someone else pays for now. Reported
Operating profit: −$8M (last 12 months). Does the business itself make money, before interest, tax and one-off gains? A net profit with an operating loss usually means the profit came from outside the business. Reported
Gross margin: Not available. Does it make money on each sale before overhead? A negative gross margin means every sale loses money. Calculated
Revenue: None yet (last 12 months). Is the business big enough to stand on its own? Under $100 million a year counts as small; under $20 million as tiny. Reported
Cash from operations: −$7M (last 12 months). Does the day-to-day business bring cash in, or use it up? Reported
Cash runway: 1.4 years ($10M cash and investments ÷ $7M a year burned). If it burns cash, how long until it runs out without raising more money? Cash includes short-term investments; burn is cash from operations minus spending on equipment. Calculated
Debt vs. cash: $0 debt ($10M cash). Could it pay off its debt? Green when cash covers the debt or debt is under 2 years of operating profit (before depreciation). Reported
Current ratio: 2.1× (short-term assets ÷ bills due within a year). Can it pay the bills due within a year from short-term assets? Below 1× means it can't, without new money. Calculated
Shareholders' equity: $7M (assets exceed debts). Do its assets exceed everything it owes? Negative equity can come from years of losses or from big buybacks, so check which. Reported
New shares issued: +85.5% a year (share count over the last 1 year). Is it selling new shares to survive? Fast-rising share counts shrink each owner's slice. Uses diluted shares from annual reports. Calculated
Going-concern warning: Yes (the annual report doubts it can keep operating for a year). Auditors must warn when they doubt a company can keep operating for the next year. Any such warning makes the verdict Speculative. From 10-K
Latest quarter profit: −$3M (quarter to 2026-09-30). The S&P 500 asks for a profit in the latest quarter as well as over the last four. A loss in the latest quarter can be the first sign of trouble, or a one-off. Reported
Altman Z-score: Not available. Edward Altman's bankruptcy-risk score from working capital, retained earnings, operating profit, market value and sales. Under 1.8 (1.1 for non-manufacturers) is the distress zone. Reported
Piotroski F-score: Not available. Joseph Piotroski's nine pass/fail checks, this year vs. last: profit, operating cash, rising return on assets, cash above profit, less debt, better liquidity, no new shares, better margins, better asset turnover. 0–3 is weak, 7–9 strong. Reported
A label for learning, not a recommendation. Speculative companies can succeed and self-funding ones can fall.
What they sell
Not broken out.
The filings don't split revenue by product in structured data.
What they sell
Not broken out.
Not broken out by product in its structured filings.
What they sell· full write-up
Not broken out.
1 · What they sell
Not available: the company's filings don't break revenue down by product or segment in structured data.
Rivals it names: While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies… From 10-K
Where each dollar goes
Not available.
Cost lines aren't reported in a comparable form.
Where each dollar goes
Not available.
Cost lines aren't reported in a comparable form.
Where each dollar goes· full write-up
Not available.
3 · Where each $1 goes
Not available: no revenue figure found in the company's structured SEC data.
Its market
1.5× the economy.
The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.
Its market
1.5× the economy.
Output growth a year, 2025–35, after inflation
Its market· full write-up
1.5× the economy.
2 · Where its markets head (10 years)
U.S. industry output growth after inflation, 2025–35
Projected to grow 1.5× as fast as the economy. Jobs in the industry: +0.7% a year. Gov projection
U.S. Bureau of Labor Statistics, Employment Projections 2025–35 (Table 2.11), released Aug 27, 2026
Market size and share
Your call.
There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.
Market size and share
Your call.
4 · Market size and share
Not available: no market size was found in the company's SEC filings. Companies usually give these in investor presentations, which aren't part of their official filings.
Market capture
Needs a market size (above). Nothing is assumed.
Life cycle
Not applicable.
Cash flow patterns don't describe a life cycle for banks and insurers, or the totals aren't reported.
Life cycle
Not applicable.
Life cycle stage
Not available: either the cash flow totals aren't in the company's structured filings, or it's a bank or insurer, where cash flow patterns don't describe a life cycle.
Earnings quality
Can't score.
The inputs aren't in its structured filings.
Earnings quality
Can't score.
M-score inputs aren't in its structured filings.
Earnings quality· full write-up
Can't score.
5 · Earnings quality
Are the profits backed by cash?
Not available.
Not available: the cash flow and balance sheet lines needed aren't in the company's structured filings.
Competitive advantage
Not measurable.
Returns on capital can't be computed from its filings (common for banks and insurers).
Competitive advantage
Not measurable.
Returns on capital can't be computed from its filings.
Competitive advantage· full write-up
Not measurable.
6 · Competitive advantage
Not available: operating profit and capital aren't in the company's structured filings.
Future bets
Not reported.
No research, equipment or commitment figures in its structured filings.
Future bets
Not reported.
Where the money for the years ahead goes
No figures in its structured filings.
Future bets· full write-up
Not reported.
7 · Future bets
Where is it putting money for the years ahead? Plans and commitments, not outcomes.
Not available in the company's structured filings.
All figures from Acurx Pharmaceuticals, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.